肿瘤心脏病学及老年肿瘤患者抗肿瘤治疗相关心血管毒性研究进展
Advances in the Study of Cardio-Oncology and Cardiovascular Toxicity Related to Tumor Cardiology in Elderly Cancer Patients
DOI: 10.12677/ACM.2020.104098, PDF,   
作者: 余其贵, 谢 军:安徽医科大学附属合肥医院,安徽 合肥
关键词: 肿瘤心脏病学抗肿瘤治疗心血管毒性研究进展Cardio-Oncology Cancer Treatment Cardiovascular Toxicity Advance
摘要: 随着人口老龄化、生活方式及饮食习惯不断改变,近年来肿瘤发病率呈逐渐增高趋势,同时随着医疗技术不断进步,癌症治疗水平不断提高,使得肿瘤患者的治愈率不断提高,患者生存时间和生活质量均得到显著提高。但是无论现有的和新兴的癌症治疗方法都会对患者的心血管系统产生毒性作用,从而影响其心血管健康,进而引起患者原有心脏病恶化或心法心血管事件,导致肿瘤患者长期发病率和死亡率明显增加,日益成为影响这类疾病预后的关键因素。对于此类患者在保证患者最有效的癌症治疗的同时,促进患者的心血管健康,最大限度降低抗肿瘤治疗心血管毒性、保护心血管系统功能,是未来研究及发展方向。
Abstract: With the aging of the population and the changes of lifestyle and eating habits in recent years, the incidence of cancer increased gradually, at the same time as medical technology continues to progress, and constantly improve the level of treatment of cancer, the tumor cure rate of patients with increasing survival time and quality of life are improved significantly. But both existing and emerging cancer treatment will produce toxic effects on the cardiovascular system, thus affecting the cardiovascular health, and patients with heart disease caused by the original deterioration or heart cardiovascular events, resulting in long-term morbidity and mortality of cancer patients in-creased significantly, has increasingly become the key factors affecting the prognosis of the disease. For such patients, while ensuring the most effective cancer treatment for patients, it is also the direction of future research and development to promote cardiovascular health of patients, minimize cardiovascular toxicity and protect cardiovascular system function.
文章引用:余其贵, 谢军. 肿瘤心脏病学及老年肿瘤患者抗肿瘤治疗相关心血管毒性研究进展[J]. 临床医学进展, 2020, 10(4): 629-635. https://doi.org/10.12677/ACM.2020.104098

参考文献

[1] Yeh, E.T. (2011) Onco-Cardiology: The Time Has Come. Texas Heart Institute Journal, 38, 246 -247.
[2] Siegel, R., DeSantis, C., Virgo, K., et al. (2012) Cancer Treatment and Survivorship Statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 220-241. [Google Scholar] [CrossRef] [PubMed]
[3] Zamorano, J.L., Lancellotti, P., Rodriguez, M.D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Journal of Heart Failure, 37, 2768-2801.
[4] Khouri, M.G., Douglas, P.S., Mackey, J., et al. (2012) Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues. Circulation, 126, 2749-2763. [Google Scholar] [CrossRef
[5] Cardinale, D., Sandri, M.T., Colombo, A., et al. (2004) Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chem-otherapy. Circulation, 109, 2749-2754. [Google Scholar] [CrossRef
[6] Hahn, V., Lenihan, D.J., Ky, B., et al. (2014) Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies. Journal of the American Heart Association, 3, E000665. [Google Scholar] [CrossRef
[7] 黄恬. 心肌肌钙蛋白I在胸部肿瘤患者放疗时心肌损伤监测中的应用价值[J]. 河北医学, 2017, 23(6): 911-914.
[8] Copur, M.S. and Obermiller, A. (2011) An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition. Clinical Col-orectal Cancer, 10, 151-156. [Google Scholar] [CrossRef] [PubMed]
[9] Wacker, A., Lersch, C., Scherpinski, U., et al. (2003) High In-cidence of Angina Pectoris in Patients Treated with 5-Fluorouracil. A Planned Surveillance Study with 102 Patients. Oncology, 65, 108-112. [Google Scholar] [CrossRef] [PubMed]
[10] Grunwald, M.R., Howie, L., Diaz Jr., L.A., et al. (2012) Takotsubo Car-diomyopathy and Fluorouracil: Case Report and Review of the Literature. Journal of Clinical Oncology, 30, e11-e14. [Google Scholar] [CrossRef
[11] Akpek, G. and Hartshorn, K.L. (1999) Failure of Oral Nitrate and Calcium Channel Blocker Therapy to Prevent 5-Fluorouracil--Related Myocardial Ischemia: A Case Report. Cancer Chemotherapy and Pharmacology, 43, 157-161. [Google Scholar] [CrossRef] [PubMed]
[12] Ferrara, N., Hillan, K.J. and Novotny, W. (2005) Bevacizumab (Avastin), a Humanized Anti-VEGF Mono-Clonal Antibody for Cancer Therapy. Biochemical and Biophysical Research Communications, 333, 328-235. [Google Scholar] [CrossRef] [PubMed]
[13] Pande, A., Lombardo, J. and Spangenthal, E. (2007) Hypertension Secondary to Anti-Angiogenic Therapy: Experience with Bevacizumab. Anticancer Research, 27, 3465-3470.
[14] Dincer, M. and Altundag, K. (2006) Angiotension-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension. Annals of Pharmacotherapy, 40, 2278-2279. [Google Scholar] [CrossRef
[15] Ksamba, T. and McDonald, D.M. (2007) Mechanisms of Adverse Effects of Anti-VEGF Therapy for Cancer. British Journal of Cancer, 96, 1788-1795. [Google Scholar] [CrossRef] [PubMed]
[16] Aparicio-Gallego, G., Afonso-Afonso, F.J., Leon-Mateos, L., et al. (2011) Molecular Basis of Hypertension Side Effects Induced by Sunitinib. Anticancer Drugs, 22, 1-8. [Google Scholar] [CrossRef
[17] Porter, G.A., Bennett, W.M. and Sheps, S.C. (1990) Cy-closporine-Associated Hypertension. National High Blood Pressure Education Program. Archives of Internal Medicine, 150, 280-283. [Google Scholar] [CrossRef] [PubMed]
[18] Skoro-Sajer, N., Marta, G., Gerges, C., et al. (2014) Surgical Specimens, Haemodynamics and Long-Term Outcomes after Pulmonary Endarterectomy. Thorax, 69, 116-122. [Google Scholar] [CrossRef] [PubMed]
[19] Yeh, E.T. and Bickford, C.L. (2009) Cardiovascular Compli-cations of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and Management. Journal of the American College of Cardiology, 53, 2231-2247. [Google Scholar] [CrossRef] [PubMed]
[20] Coughlin, S., Das, S., Lee, J., et al. (2008) Capecitabine Induced Vasospastic Angina. International Journal of Cardiology, 130, 34-36. [Google Scholar] [CrossRef] [PubMed]
[21] Nieto, Y., Cagnoni, P., Bearman, S.I., et al. (2000) Cardiac Tox-icity Following High Dose Cyclophoph Amide, Cisplatin and BCNU for Breast Cancer. Biology of Blood and Marrow Transplantation, 6, 198-203. [Google Scholar] [CrossRef
[22] Priori, S.G., Blomström-Lundqvist, C., Mazzanti, A., et al. (2015) 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal, 36, 2793-2867.
[23] Skoro-Sajer, N., Hack, N., Sadushi-Koliçi, R., et al. (2009) Pulmonary Vascular Reactivity and Prognosis in Patients with Chronic Thromboembolic Pulmonary Hypertension A Pilot Study. Circulation, 119, 298-305. [Google Scholar] [CrossRef
[24] Bonderman, D., Skoro-Sajer, N., Jakowitsch, J., et al. (2007) Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension. Circulation, 115, 2153-2158. [Google Scholar] [CrossRef
[25] Jamieson, S.W., Kapelanski, D.P., et al. (2003) Pulmonary Endarterectomy: Experience and Lessons Learned in 1,500 Cases. The Annals of Thoracic Surgery, 76, 1457-1462. [Google Scholar] [CrossRef
[26] Dartevelle, P., Fadel, E., Mussot, S., et al. (2004) Chronic Thromboembolic Pulmonary Hypertension. European Respiratory Society, 23, 637-648. [Google Scholar] [CrossRef] [PubMed]
[27] Ranpura, V., Hapani, S., Chuang, J. and Wu, S. (2010) Risk of Cardiac Ischemia and Arterial Thromboembolic Events with the Angiogenesis Inhibitor Bevacizuab in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. Acta Oncologica, 49, 287-297. [Google Scholar] [CrossRef] [PubMed]
[28] Zangari, M., Fink, L.M., Elice, F., Zhan, F. and Adcock, D.M. (2009) Thrombotic Events in Patients with Cancer Receiving Antiangiogenesis Agents. Journal of Clinical Oncology, 27, 4865-4873. [Google Scholar] [CrossRef
[29] Bair, S.M., Choueiri, T.K. and Moslehi, J. (2013) Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors: Emerging Evidence and Evolving Perspective. Trends in Cardiovascular Medicine, 23, 104-113. [Google Scholar] [CrossRef] [PubMed]
[30] Kunihara, T., Gerdts, J., Groesdonk, H., et al. (2011) Predictors of Postoperative Outcome after Pulmonary Endarterectomy from a 14-Year Experience with 279 Patients. European Journal of Cardio-Thoracic Surgery, 40, 154-161. [Google Scholar] [CrossRef] [PubMed]
[31] Jaworski, C., Mariani, J.A., Wheeler, G., et al. (2013) Cardiac Complications of Thoracic Irradiation. Journal of the American College of Cardiology, 61, 2319-2328. [Google Scholar] [CrossRef] [PubMed]
[32] Hull, M.C., Morris, C.G., Pepine, C.J. and Mendenhall, N.P. (2003) Valvular Dysfunction and Carotid, Subclavian and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated with Radiation Therapy. Journal of the American Medical Association, 290, 2831-2837. [Google Scholar] [CrossRef] [PubMed]
[33] Hering, D., Faber, L. and Horstkotte, D. (2003) Echocardiographic Features of Radiation-Associated Valvular Disease. American Journal of Cardiology, 92, 226-230. [Google Scholar] [CrossRef
[34] Vahanian, A., Alfieri, O., Andreotti, F., et al. (2012) Guidelines on the Management of Valvular Heart Disease (Version 2012). European Heart Journal, 33, 2451-2496. [Google Scholar] [CrossRef] [PubMed]
[35] Ogino, H., Ando, M., Matsuda, H., et al. (2006) Japanese Sin-gle-Center Experience of Surgery for Chronic Thrombo-Embolic Pulmonary Hypertension. The Annals of Thoracic Surgery, 82, 630-636. [Google Scholar] [CrossRef] [PubMed]
[36] Mortimer, J.E., Crowley, J., Eyre, H. and Weiden, P. (1992) A Phase II Randomized Study Comparing Sequential and Combined Intraarterial Cisplatin and Radiation Therapy in Primary Brain Tumors. A Southwest Oncology Group Study. Cancer, 69, 1220-1223. [Google Scholar] [CrossRef] [PubMed]
[37] Kramm, T., Eberle, B., Guth, S., et al. (2005) Inhaled Iloprost to Control Residual Pulmonary Hypertension Following Pulmonary Endarterectomy. European Journal of Cardio-Thoracic Surgery, 28, 882-888. [Google Scholar] [CrossRef] [PubMed]
[38] Ghofrani, H.A., D’Armini, A.M., Grimminger, F., et al. (2013) Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. The New England Journal of Med-icine, 369, 319-329. [Google Scholar] [CrossRef
[39] Seemann, I., Gillette, K. and Visser, N.L. (2012) Irradiation Induced Modest Changes in Murine Cardiac Function Despite Progressive Structural Damage to the Myocardium and Microvasculature. Radiotherapy and Oncology, 103, 143-150. [Google Scholar] [CrossRef] [PubMed]
[40] Stewart, J.R., Fajardo, L.F., Gillette, S.M., et al. (1995) Radia-tion Injury to the Heart. International Journal of Radiation Oncology, Biology, Physics, 31, 1205-1211. [Google Scholar] [CrossRef] [PubMed]
[41] 彭毅, 谭文勇. 抗肿瘤治疗相关的心脏血管毒性: 肿瘤心脏病学亟待跟进[J]. 临床与病理杂志, 2015, 35(3): 433-443.